Fig. 4From: Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancerExpression of immune checkpoint biomarkers over time in each cohort. (A) PD-L1, (B) PD-L2, (C) B7-H3, (D) CTLA-4. Histograms made to depict percentage of total CTCs from each patient. Percentage of patients in each cohort with at least one marker-positive CTC at each timepoint (E). Percentage of patients in each cohort with at least 50% marker-positive CTCs at each timepoint (F). ARSI: Androgen receptor signaling inhibitorsBack to article page